Public health perspectives on testing for colorectal cancer susceptibility genes

Steven Scott Coughlin, Daniel S. Miller

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Context: About 131,600 new cases of colorectal cancer will be diagnosed in the United States in 1998. About 27,900 men and 28,600 women will die from colorectal cancer in 1998. Mutations to the hMSH2 gene on chromosome 2p and to the hMLH1 gene on chromosome 3p have been identified as causes of colorectal cancer. These mismatch repair genes, which have recently been cloned, account for most cases of hereditary nonpolyposis colorectal cancer (HNPCC), one of the most common cancer susceptibility syndromes known. The carrier frequency of hMSH2 and hMLH1 gene mutations in the U.S. population is unknown. An adenomatous polyposis coli (APC) gene variant (I1307K allele), which was recently reported in 1 in 17 Ashkenazi Jewish persons, may double the risk for colorectal cancer in that population. Conclusions: The use of genetic tests for susceptibility to cancer of the colon and other sites needs careful scrutiny. Several issues must be addressed before such tests can be recommended for population-based prevention programs. For example, the screening of population subgroups raises concern about potential discrimination and stigmatization. Before genetic tests for colorectal cancer are incorporated into future programs, the safety, effectiveness, and quality of these tests must be evaluated.

Original languageEnglish (US)
Pages (from-to)99-104
Number of pages6
JournalAmerican Journal of Preventive Medicine
Volume16
Issue number2
DOIs
StatePublished - Jan 1 1999
Externally publishedYes

Fingerprint

Neoplasm Genes
Colorectal Neoplasms
Public Health
Population
Genes
Chromosomes
APC Genes
Hereditary Nonpolyposis Colorectal Neoplasms
Stereotyping
Mutation
DNA Mismatch Repair
Program Evaluation
Genetic Predisposition to Disease
Colonic Neoplasms
Alleles
Safety
Neoplasms

Keywords

  • Cancer genetics
  • Colorectal cancer
  • Genetic testing
  • Germline mutations
  • Prevention effectiveness
  • Screening

ASJC Scopus subject areas

  • Epidemiology
  • Public Health, Environmental and Occupational Health

Cite this

Public health perspectives on testing for colorectal cancer susceptibility genes. / Coughlin, Steven Scott; Miller, Daniel S.

In: American Journal of Preventive Medicine, Vol. 16, No. 2, 01.01.1999, p. 99-104.

Research output: Contribution to journalArticle

@article{485a7038e28f4effa5dc43e1f86fbe08,
title = "Public health perspectives on testing for colorectal cancer susceptibility genes",
abstract = "Context: About 131,600 new cases of colorectal cancer will be diagnosed in the United States in 1998. About 27,900 men and 28,600 women will die from colorectal cancer in 1998. Mutations to the hMSH2 gene on chromosome 2p and to the hMLH1 gene on chromosome 3p have been identified as causes of colorectal cancer. These mismatch repair genes, which have recently been cloned, account for most cases of hereditary nonpolyposis colorectal cancer (HNPCC), one of the most common cancer susceptibility syndromes known. The carrier frequency of hMSH2 and hMLH1 gene mutations in the U.S. population is unknown. An adenomatous polyposis coli (APC) gene variant (I1307K allele), which was recently reported in 1 in 17 Ashkenazi Jewish persons, may double the risk for colorectal cancer in that population. Conclusions: The use of genetic tests for susceptibility to cancer of the colon and other sites needs careful scrutiny. Several issues must be addressed before such tests can be recommended for population-based prevention programs. For example, the screening of population subgroups raises concern about potential discrimination and stigmatization. Before genetic tests for colorectal cancer are incorporated into future programs, the safety, effectiveness, and quality of these tests must be evaluated.",
keywords = "Cancer genetics, Colorectal cancer, Genetic testing, Germline mutations, Prevention effectiveness, Screening",
author = "Coughlin, {Steven Scott} and Miller, {Daniel S.}",
year = "1999",
month = "1",
day = "1",
doi = "10.1016/S0749-3797(98)00137-8",
language = "English (US)",
volume = "16",
pages = "99--104",
journal = "American Journal of Preventive Medicine",
issn = "0749-3797",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Public health perspectives on testing for colorectal cancer susceptibility genes

AU - Coughlin, Steven Scott

AU - Miller, Daniel S.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Context: About 131,600 new cases of colorectal cancer will be diagnosed in the United States in 1998. About 27,900 men and 28,600 women will die from colorectal cancer in 1998. Mutations to the hMSH2 gene on chromosome 2p and to the hMLH1 gene on chromosome 3p have been identified as causes of colorectal cancer. These mismatch repair genes, which have recently been cloned, account for most cases of hereditary nonpolyposis colorectal cancer (HNPCC), one of the most common cancer susceptibility syndromes known. The carrier frequency of hMSH2 and hMLH1 gene mutations in the U.S. population is unknown. An adenomatous polyposis coli (APC) gene variant (I1307K allele), which was recently reported in 1 in 17 Ashkenazi Jewish persons, may double the risk for colorectal cancer in that population. Conclusions: The use of genetic tests for susceptibility to cancer of the colon and other sites needs careful scrutiny. Several issues must be addressed before such tests can be recommended for population-based prevention programs. For example, the screening of population subgroups raises concern about potential discrimination and stigmatization. Before genetic tests for colorectal cancer are incorporated into future programs, the safety, effectiveness, and quality of these tests must be evaluated.

AB - Context: About 131,600 new cases of colorectal cancer will be diagnosed in the United States in 1998. About 27,900 men and 28,600 women will die from colorectal cancer in 1998. Mutations to the hMSH2 gene on chromosome 2p and to the hMLH1 gene on chromosome 3p have been identified as causes of colorectal cancer. These mismatch repair genes, which have recently been cloned, account for most cases of hereditary nonpolyposis colorectal cancer (HNPCC), one of the most common cancer susceptibility syndromes known. The carrier frequency of hMSH2 and hMLH1 gene mutations in the U.S. population is unknown. An adenomatous polyposis coli (APC) gene variant (I1307K allele), which was recently reported in 1 in 17 Ashkenazi Jewish persons, may double the risk for colorectal cancer in that population. Conclusions: The use of genetic tests for susceptibility to cancer of the colon and other sites needs careful scrutiny. Several issues must be addressed before such tests can be recommended for population-based prevention programs. For example, the screening of population subgroups raises concern about potential discrimination and stigmatization. Before genetic tests for colorectal cancer are incorporated into future programs, the safety, effectiveness, and quality of these tests must be evaluated.

KW - Cancer genetics

KW - Colorectal cancer

KW - Genetic testing

KW - Germline mutations

KW - Prevention effectiveness

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=0032987574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032987574&partnerID=8YFLogxK

U2 - 10.1016/S0749-3797(98)00137-8

DO - 10.1016/S0749-3797(98)00137-8

M3 - Article

C2 - 10343885

AN - SCOPUS:0032987574

VL - 16

SP - 99

EP - 104

JO - American Journal of Preventive Medicine

JF - American Journal of Preventive Medicine

SN - 0749-3797

IS - 2

ER -